Trial Profile
A Randomized Phase II Window of Opportunity Clinical Trial of IL-4 +/- PD-1 Inhibition in Early-stage ER+ HER2- Breast Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary) ; Dupilumab (Primary)
- Indications Breast cancer; HER2 negative breast cancer
- Focus Pharmacodynamics
- 04 Aug 2023 New trial record